{
    "nct_id": "NCT03735680",
    "official_title": "A Phase 2a, Single-dose, Open-label Study to Evaluate Diagnostic Performance, Safety & Timing of Postdose Imaging of ONM-100, an Intraoperative Fluorescence Imaging Agent for the Detection of Cancer, in Patients With Solid Tumors Undergoing Routine Surgery",
    "inclusion_criteria": "* Biopsy-confirmed diagnosis of primary or recurrent respective tumor type and scheduled to undergo surgical resection\n* Part 1: Biopsy-confirmed diagnosis of head and neck squamous cell carcinoma (HNSCC) or breast cancer\n* Part 2: Biopsy-confirmed diagnosis of HNSCC, breast cancer, colorectal cancer, prostate cancer, ovarian cancer, urothelial carcinoma and non-small cell lung cancer.\n* Part 3: Stage 2 to 4 HNSCC Including T0 or Tx unknown Primary cancers\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Histologically diagnosed by an excisional biopsy procedure\n* Tumors at sites of which the surgeon would assess that in vivo intraoperative imaging would not be feasible\n* Life expectancy <12 weeks\n* Hepatic impairment (Child-Pugh score >5) or significant liver disease including active hepatitis or cirrhosis",
    "miscellaneous_criteria": ""
}